
    
      Observational study to assess effects of nusinersen on motor function in adult patients with
      spinal muscular atrophy who are both ambulatory and non-ambulatory. Subjects will receive
      standard of care with nusinersen intrathecal injection and undergo baseline and every 6 month
      motor assessments and pulmonary function testing during the first two years of treatment with
      nusinersen.
    
  